UCL logo

UCL Discovery

UCL home » Library Services » Electronic resources » UCL Discovery

Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy

Kesselring, AM; Wit, FW; Sabin, CA; Lundgren, JD; Gill, MJ; Gatell, JM; Rauch, A; ... Nevirapine Toxicity Multicohort, ; + view all (2009) Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy. AIDS , 23 (13) 1689 - 1699. 10.1097/QAD.0b013e32832d3b54.

Full text not available from this repository.

Abstract

Background: This collaboration of seven observational clinical cohorts investigated risk factors for treatment-limiting toxicities in both anti retroviral-naive and experienced patients starting nevirapine-based combination antiretroviral therapy (NVPc).Methods: Patients starting NVPc after 1 January 1998 were included. CD4 cell count at starting NVPc was classified as high (>400/mu l/>250/mu l for men/women, respectively) or low. Cox models were used to investigate risk factors for discontinuations due to hypersensitivity reactions (HSR, n = 6547) and discontinuation of NVPc due to treatment-limiting toxicities and/or patient/physician choice (TOXPC, n = 10 186). Patients were classified according to prior antiretroviral treatment experience and CD4 cell count/viral load at start NVPc. Models were stratified by cohort and adjusted for age, sex, nadir CD4 cell count, calendar year of starting NVPc and mode of transmission.Results: Median time from starting NVPc to TOXPC and HSR were 162 days [interquartile range (IQR) 31 -737] and 30 days (IQR 17-60), respectively. In adjusted Cox analyses, compared to naive patients with a low CD4 cell count, treatment-experienced patients with high CD4 cell count and viral load more than 400 had a significantly increased risk for HSR [hazard ratio 1.45, confidence interval (CI) 1.03-2.03] and TOXPC within 18 weeks (hazard ratio 1.34, Cl 1.08-1.67). In contrast, treatment-experienced patients with high CD4 cell count and viral load less than 400 had no increased risk for HSR 1.10 (0.82-1.46) or TOXPC within 18 weeks(hazard ratio 0.94, Cl 0.78-1.13).Conclusion: Our results suggest it may be relatively well tolerated to initiate NVPc in anti retroviral-experienced patients with high CD4 cell counts provided there is no detectable viremia. (C) 2009 Wolters Kluwer Health | Lippincott Williams & Wilkins

Type: Article
Title: Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy
DOI: 10.1097/QAD.0b013e32832d3b54
Keywords: CD4 cell count, HIV, nevirapine, toxicity, viral load, HIV-INFECTED PATIENTS, CD4 CELL COUNTS, PROTEASE INHIBITORS, HIV-1-INFECTED PATIENTS, PROSPECTIVE COHORT, CONTROLLED TRIAL, DOUBLE-BLIND, HYPERSENSITIVITY, RASH, HEPATOTOXICITY
UCL classification: UCL > Provost and Vice Provost Offices
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Pop Health Sciences > Institute for Global Health
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Pop Health Sciences > Institute for Global Health > Infection and Population Health
URI: http://discovery.ucl.ac.uk/id/eprint/164887
Downloads since deposit
0Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item